219 related articles for article (PubMed ID: 9324182)
1. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
Terra SG; Spitzer TR; Tsunoda SM
Pharmacotherapy; 1997; 17(5):929-37. PubMed ID: 9324182
[TBL] [Abstract][Full Text] [Related]
2. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
Baglin TP; Harper P; Marcus RE
Bone Marrow Transplant; 1990 Jun; 5(6):439-41. PubMed ID: 2369685
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].
Yoshimi A; Kato K; Maeda N; Matsuyama T; Kojima S
Rinsho Ketsueki; 2000 Feb; 41(2):103-8. PubMed ID: 10723238
[TBL] [Abstract][Full Text] [Related]
4. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients.
Yu LC; Malkani I; Regueira O; Ode DL; Warrier RP
Am J Hematol; 1994 Jul; 46(3):194-8. PubMed ID: 8192148
[TBL] [Abstract][Full Text] [Related]
5. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
Simpson DR; Browett PJ; Doak PB; Palmer SJ
Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
[TBL] [Abstract][Full Text] [Related]
7. Veno-occlusive disease of the liver complicating bone marrow transplantation.
Baglin TP
Bone Marrow Transplant; 1994 Jan; 13(1):1-4. PubMed ID: 8019444
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
Goldberg SL; Shubert J; Rao AK; Redei I; Klumpp TR; Mangan KF
Bone Marrow Transplant; 1996 Sep; 18(3):633-6. PubMed ID: 8879629
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
[TBL] [Abstract][Full Text] [Related]
10. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.
Bajwa RP; Cant AJ; Abinun M; Flood TJ; Hodges S; Hale JP; Skinner R
Bone Marrow Transplant; 2003 Apr; 31(7):591-7. PubMed ID: 12692627
[TBL] [Abstract][Full Text] [Related]
11. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate.
Patton DF; Harper JL; Wooldridge TN; Gordon BG; Coccia P; Haire WD
Bone Marrow Transplant; 1996 Mar; 17(3):443-7. PubMed ID: 8704704
[TBL] [Abstract][Full Text] [Related]
12. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
Hägglund H; Ringdén O; Ljungman P; Winiarski J; Ericzon B; Tydén G
Transplant Proc; 1995 Dec; 27(6):3535. PubMed ID: 8540088
[No Abstract] [Full Text] [Related]
13. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
Leahey AM; Bunin NJ
Bone Marrow Transplant; 1996 Jun; 17(6):1101-4. PubMed ID: 8807121
[TBL] [Abstract][Full Text] [Related]
15. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
[TBL] [Abstract][Full Text] [Related]
16. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
[TBL] [Abstract][Full Text] [Related]
17. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
Heying R; Nürnberger W; Spiekerkötter U; Göbel U
Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
[TBL] [Abstract][Full Text] [Related]
18. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
Feldman L; Gabai E; Milovic V; Jaimovich G
Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875
[No Abstract] [Full Text] [Related]
19. Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
Söhngen D; Bauser U; Boogen C; Aul C; Frieling T; Germing U; Schneider P; Kobbe G; Heyll A
Thromb Haemost; 1997 Oct; 78(4):1299-300. PubMed ID: 9365005
[No Abstract] [Full Text] [Related]
20. Fatal hemorrhage after recombinant tissue plasminogen activator therapy for hepatic veno-occlusive disease complicating autologous BMT.
Otheo de Tejada E; Maldonado MS; Camarero C; Muñoz A
Bone Marrow Transplant; 1994 Jul; 14(1):176-7. PubMed ID: 7951113
[No Abstract] [Full Text] [Related]
[Next] [New Search]